Literature DB >> 29990501

Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.

Hanlin Zeng1, Aparna Jorapur1, A Hunter Shain2, Ursula E Lang2, Rodrigo Torres1, Yuntian Zhang1, Andrew S McNeal1, Thomas Botton2, Jue Lin3, Matthew Donne4, Ingmar N Bastian2, Richard Yu5, Jeffrey P North6, Laura Pincus6, Beth S Ruben7, Nancy M Joseph8, Iwei Yeh2, Boris C Bastian2, Robert L Judson9.   

Abstract

Loss of the CDKN2A tumor suppressor is associated with melanoma metastasis, but the mechanisms connecting the phenomena are unknown. Using CRISPR-Cas9 to engineer a cellular model of melanoma initiation from primary human melanocytes, we discovered that a lineage-restricted transcription factor, BRN2, is downstream of CDKN2A and directly regulated by E2F1. In a cohort of melanocytic tumors that capture distinct progression stages, we observed that CDKN2A loss coincides with both the onset of invasive behavior and increased BRN2 expression. Loss of the CDKN2A protein product p16INK4A permitted metastatic dissemination of human melanoma lines in mice, a phenotype rescued by inhibition of BRN2. These results demonstrate a mechanism by which CDKN2A suppresses the initiation of melanoma invasion through inhibition of BRN2.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRN2; CDKN2A; CRISPR engineering; E2F1; invasion; melanocytes; melanoma

Mesh:

Substances:

Year:  2018        PMID: 29990501      PMCID: PMC6084788          DOI: 10.1016/j.ccell.2018.05.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  71 in total

1.  Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation.

Authors:  Nathan Salomonis; Christopher R Schlieve; Laura Pereira; Christine Wahlquist; Alexandre Colas; Alexander C Zambon; Karen Vranizan; Matthew J Spindler; Alexander R Pico; Melissa S Cline; Tyson A Clark; Alan Williams; John E Blume; Eva Samal; Mark Mercola; Bradley J Merrill; Bruce R Conklin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

2.  Population-based prevalence of CDKN2A mutations in Utah melanoma families.

Authors:  Mark J Eliason; April A Larson; Scott R Florell; John J Zone; Lisa A Cannon-Albright; Wolfram E Samlowski; Sancy A Leachman
Journal:  J Invest Dermatol       Date:  2006-03       Impact factor: 8.551

3.  The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts.

Authors:  R Fåhraeus; D P Lane
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

4.  Germline p16 mutations in familial melanoma.

Authors:  C J Hussussian; J P Struewing; A M Goldstein; P A Higgins; D S Ally; M D Sheahan; W H Clark; M A Tucker; N C Dracopoli
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

5.  Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.

Authors:  M G FitzGerald; D P Harkin; S Silva-Arrieta; D J MacDonald; L C Lucchina; H Unsal; E O'Neill; J Koh; D M Finkelstein; K J Isselbacher; A J Sober; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

6.  Loss of p16 expression is associated with histological features of melanoma invasion.

Authors:  S J Pavey; M C Cummings; D C Whiteman; M Castellano; M D Walsh; B G Gabrielli; A Green; N K Hayward
Journal:  Melanoma Res       Date:  2002-12       Impact factor: 3.599

7.  Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.

Authors:  Julien Ackermann; Manon Frutschi; Kostas Kaloulis; Thomas McKee; Andreas Trumpp; Friedrich Beermann
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

8.  Characteristics of cultured human melanocytes isolated from different stages of tumor progression.

Authors:  M Herlyn; J Thurin; G Balaban; J L Bennicelli; D Herlyn; D E Elder; E Bondi; D Guerry; P Nowell; W H Clark
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

Review 9.  POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis.

Authors:  Anthony L Cook; Richard A Sturm
Journal:  Pigment Cell Melanoma Res       Date:  2008-10-22       Impact factor: 4.693

10.  Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation.

Authors:  S M Kumar; J Dai; S Li; R Yang; H Yu; K L Nathanson; S Liu; H Zhou; J Guo; X Xu
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

View more
  29 in total

1.  The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.

Authors:  Jae Hyuk Yoo; Samuel W Brady; Lehi Acosta-Alvarez; Aaron Rogers; Jingfu Peng; Lise K Sorensen; Roger K Wolff; Tara Mleynek; Donghan Shin; Coulson P Rich; David A Kircher; Andrea Bild; Shannon J Odelberg; Dean Y Li; Sheri L Holmen; Allie H Grossmann
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

Review 2.  BRAF in malignant melanoma progression and metastasis: potentials and challenges.

Authors:  Aljawharah Alqathama
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

3.  Stepwise-edited, human melanoma models reveal mutations' effect on tumor and microenvironment.

Authors:  Eran Hodis; Elena Torlai Triglia; John Y H Kwon; Tommaso Biancalani; Labib R Zakka; Saurabh Parkar; Jan-Christian Hütter; Lorenzo Buffoni; Toni M Delorey; Devan Phillips; Danielle Dionne; Lan T Nguyen; Denis Schapiro; Zoltan Maliga; Connor A Jacobson; Ayal Hendel; Orit Rozenblatt-Rosen; Martin C Mihm; Levi A Garraway; Aviv Regev
Journal:  Science       Date:  2022-04-29       Impact factor: 63.714

4.  Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.

Authors:  A Hunter Shain; Nancy M Joseph; Richard Yu; Jamal Benhamida; Shanshan Liu; Tarl Prow; Beth Ruben; Jeffrey North; Laura Pincus; Iwei Yeh; Robert Judson; Boris C Bastian
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

Review 5.  The Evolution of Melanoma - Moving beyond Binary Models of Genetic Progression.

Authors:  Hanlin Zeng; Robert L Judson-Torres; A Hunter Shain
Journal:  J Invest Dermatol       Date:  2019-10-14       Impact factor: 8.551

Review 6.  Rethinking the biology of metastatic melanoma: a holistic approach.

Authors:  Hendrik Hld Vandyck; Lisa M Hillen; Francesca M Bosisio; Joost van den Oord; Axel Zur Hausen; Véronique Winnepenninckx
Journal:  Cancer Metastasis Rev       Date:  2021-04-19       Impact factor: 9.264

7.  STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.

Authors:  Biniam Adane; Gabriela Alexe; Bo Kyung A Seong; Diana Lu; Elizabeth E Hwang; Denes Hnisz; Caleb A Lareau; Linda Ross; Shan Lin; Filemon S Dela Cruz; Melissa Richardson; Abraham S Weintraub; Sarah Wang; Amanda Balboni Iniguez; Neekesh V Dharia; Amy Saur Conway; Amanda L Robichaud; Benjamin Tanenbaum; John M Krill-Burger; Francisca Vazquez; Monica Schenone; Jason N Berman; Andrew L Kung; Steven A Carr; Martin J Aryee; Richard A Young; Brian D Crompton; Kimberly Stegmaier
Journal:  Cancer Cell       Date:  2021-06-14       Impact factor: 38.585

8.  Prediction of Specific Subtypes and Common Markers of Non-Small Cell Lung Cancer Based on Competing Endogenous RNA Network.

Authors:  Yao Liu; Hao Wang; Wenhan Yang; Youhui Qian
Journal:  Med Sci Monit       Date:  2020-07-13

9.  BRN 2 Invade.

Authors:  Gaurav Pathria; Ze'ev A Ronai
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

10.  BRN2 is a non-canonical melanoma tumor-suppressor.

Authors:  Michael Hamm; Pierre Sohier; Valérie Petit; Jérémy H Raymond; Véronique Delmas; Madeleine Le Coz; Franck Gesbert; Colin Kenny; Zackie Aktary; Marie Pouteaux; Florian Rambow; Alain Sarasin; Nisamanee Charoenchon; Alfonso Bellacosa; Luis Sanchez-Del-Campo; Laura Mosteo; Martin Lauss; Dies Meijer; Eirikur Steingrimsson; Göran B Jönsson; Robert A Cornell; Irwin Davidson; Colin R Goding; Lionel Larue
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.